Voluntis (Paris:VTX) (Euronext Paris, Mnemo: VTX – ISIN: FR0004183960), a company specialized in digital therapeutics, announces today that it has entered into a collaboration with AbbVie, a research-based global biopharmaceutical company, to enhance patient care coordination in immunology with innovative digital therapeutic software. Together the companies will leverage Voluntis’ proven Theraxium technology to make this new solution available to patients and providers in the United States.

Pierre Leurent, CEO of Voluntis: “This collaboration illustrates the value of Theraxium in powering next-generation digital therapeutics in wide-ranging therapeutic areas.”